Skip to Content
Merck
CN

Blocking the formation of radiation-induced breast cancer stem cells.

Oncotarget (2014-07-09)
Yangyang Wang, Wende Li, Shalin S Patel, Juan Cong, Nan Zhang, Francesco Sabbatino, Xiaoyan Liu, Yuan Qi, Peigen Huang, Hang Lee, Alphonse Taghian, Jian-Jian Li, Albert B DeLeo, Soldano Ferrone, Michael W Epperly, Cristina R Ferrone, Amy Ly, Elena F Brachtel, Xinhui Wang
ABSTRACT

The goal of adjuvant (post-surgery) radiation therapy (RT) for breast cancer (BC) is to eliminate residual cancer cells, leading to better local tumor control and thus improving patient survival. However, radioresistance increases the risk of tumor recurrence and negatively affects survival. Recent evidence shows that breast cancer stem cells (BCSCs) are radiation-resistant and that relatively differentiated BC cells can be reprogrammed into induced BCSCs (iBCSCs) via radiation-induced re-expression of the stemness genes. Here we show that in irradiation (IR)-treated mice bearing syngeneic mammary tumors, IR-induced stemness correlated with increased spontaneous lung metastasis (51.7%). However, IR-induced stemness was blocked by targeting the NF-κB- stemness gene pathway with disulfiram (DSF)and Copper (Cu2+). DSF is an inhibitor of aldehyde dehydrogenase (ALDH) and an FDA-approved drug for treating alcoholism. DSF binds to Cu2+ to form DSF-Cu complexes (DSF/Cu), which act as a potent apoptosis inducer and an effective proteasome inhibitor, which, in turn, inhibits NF-κB activation. Treatment of mice with RT and DSF significantly inhibited mammary primary tumor growth (79.4%) and spontaneous lung metastasis (89.6%) compared to vehicle treated mice. This anti-tumor efficacy was associated with decreased stem cell properties (or stemness) in tumors. We expect that these results will spark clinical investigation of RT and DSF as a novel combinatorial treatment for breast cancer.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Eosin Y, 75% (HPLC)
Sigma-Aldrich
D-Luciferin, synthetic, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
D-Luciferin, synthetic
Sigma-Aldrich
Eosin Y, Dye content ~99 %
Sigma-Aldrich
IMD-0354, ≥98% (HPLC), solid
Sigma-Aldrich
Eosin Y disodium salt, certified by the BSC
Sigma-Aldrich
Copper(II) D-gluconate, 98%
Sigma-Aldrich
Eosin Y disodium salt, ≥85 % by HPLC
Sigma-Aldrich
Eosin Y solution, 5 wt. % in H2O
Disulfiram, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
MISSION® esiRNA, targeting human RELA
Sigma-Aldrich
Potassium hydride, 30 wt % dispersion in mineral oil
SAFC
L-Glutamine
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Rela
Sigma-Aldrich
Hematoxylin, certified by the BSC
Sigma-Aldrich
Copper(II) chloride, powder, 99%
Sigma-Aldrich
Copper(II) chloride, 99.999% trace metals basis
Sigma-Aldrich
Hematoxylin
Sigma-Aldrich
Copper(II) chloride, anhydrous, powder, ≥99.995% trace metals basis
Sigma-Aldrich
Copper(II) chloride, 97%
Supelco
L-Glutamine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Glutamine, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
L-Glutamine, γ-irradiated, BioXtra, suitable for cell culture
Supelco
L-Glutamine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Glutamine, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
L-Glutamine
Sigma-Aldrich
L-Glutamine, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
Tetraethylthiuram disulfide, ≥97.0% (S)
Sigma-Aldrich
L-Glutamine, Vetec, reagent grade, ≥99%
Sigma-Aldrich
N-Acetyl-L-cysteine, Sigma Grade, ≥99% (TLC), powder